Recent News

By Category: Countermeasures

FDA Launches New Outbreak Response Team

The Food and Drug Administration (FDA) has assembled a new network of epidemiologists and other public health experts in hopes of responding more quickly and effectively to outbreaks of foodborne illness.Dubbed the Coordinated Outbreak Response and Evaluation (CORE) Network, the team will be directed by Dr. Kathleen F. Gensheimer, the former Maine state epidemiologist. As Read More »

September 16, 2011
| Filed under North America, Agriculture, Countermeasures, and Public Health
Share

Emergent BioSolutions Co-Hosts Biopreparedness Conference with the French High…

(MarketWatch) Emergent BioSolutions Inc. is co-hosting “Anthrax: Threat and Response,” a conference organized by the French High Committee for Civil Defense to discuss anthrax preparedness and response. The conference, which brings together military and civilian representatives involved in biological threat management in France, features topics on research programs, threat detection, hospital and medical chain preparedness, Read More »

September 12, 2011
| Filed under Europe, North America, Biotechnology, Countermeasures, and Research
Share

PharmAthene completes final commercial scale-up activities for SparVax

(Pharmaceutical Business Review) PharmAthene has accomplished significant progress in the development of SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine. PharmAthene's rPA anthrax vaccine program has been funded in whole or in part with Federal funds …

September 12, 2011
| Filed under North America, Biotechnology, and Countermeasures
Share

Biodefence since 9/11: The price of protection

(Nature.com) It took one routine smallpox vaccination to expose the holes in the United States’ defences against bioterrorism. In January 2009, the jab was given to 20-year-old Lance Corporal Cory Belken of the US Marine Corps, as it is to many members of the military who are about to be deployed abroad, to protect him Read More »

September 8, 2011
| Filed under North America, Countermeasures, and Public Health
Share

GSK Awarded $38.5M Contract to Develop Antibiotic for Biodefense and Drug …

(Genetic Engineering News) “This commercial-plus-biodefense strategy creates a sustainable, cost-effective business model for private industry and taxpayers, and it promotes a warm base manufacturing capability for use in a public health emergency,” comments BARDA director Robin …